Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 2/20 | 0.45 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 5/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30642265 | 0.97 | KRAS (0.44) | KRASSHMT2CCNT1CDK9GAA | |
| SCHEMBL16122418 | 0.97 | KRAS (0.44) | KRASSHMT2CCNT1CDK9GAA | |
| SCHEMBL16129267 | 0.89 | KRAS (0.43) | KRASSHMT2CCNT1CDK9GAA | |
| SCHEMBL16122588 | 0.88 | KRAS (0.44) | KRASSHMT2CCNT1CDK9STS | |
| SCHEMBL30642257 | 0.88 | KRAS (0.44) | KRASSHMT2CCNT1CDK9STS | |
| SCHEMBL16102313 | 0.88 | KRAS (0.46) | KRASSHMT2CCNT1CDK9GAA | |
| SCHEMBL16093602 | 0.88 | KRAS (0.46) | KRASSHMT2CCNT1CDK9GAA | |
| SCHEMBL16093741 | 0.86 | KRAS (0.45) | KRASSHMT2CCNT1CDK9GAA | |
| SCHEMBL16098954 | 0.86 | KRAS (0.48) | KRASSHMT2CCNT1CDK9GAA | |
| SCHEMBL30642275 | 0.86 | KRAS (0.48) | KRASSHMT2CCNT1CDK9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | KRAS 1/4885SHMT2 1327/4885CCNT1 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.